Skip to content

Colorado’s first licensed cannabis R&D firm to study marijuana’s effect on Alzheimer’s disease

March 6, 2020 / Arfinn Med MD /

Colorado’s first licensed cannabis R&D firm to study marijuana’s effect on Alzheimer’s disease

A Denver-based company hopes to be the state’s first to study the effects of marijuana on Alzheimer’s disease, thanks to a newly available research and development license in the city.

MedPharm Holdings plans to apply for a Denver marijuana R&D license to test delta-9 tetrahydrocannabinol (THC), cannabidiol (CBD) and other cannabinoids’ effects on Alzheimer’s and dementia patients.

According to the Alzheimer’s Association, 5.8 million Americans have the disease, a degenerative brain disorder that affects a person’s memory and thinking skills. While there are drugs that help ease symptoms, they do not change the course of the disease.

Albert Gutierrez, CEO of MedPharm, sees Alzheimer’s as “one of the biggest things that’s plaguing our country now and in the future.” That’s why he’s excited about cannabis’ potential to treat it.

Read Full Article Here

Stories you may be interested in

Florida’s largest cannabis company makes a deal to carry edible marijuana products

TALLAHASSEE The state’s first and largest medical marijuana provider, Trulieve, signed an exclusive deal to bring high-end edible marijuana products to Florida, the company announced Wednesday. Binske, the Colorado-based company, began operations just two years ago, markets “an experience” through their top-shelf products. Florida’s 162,000 registered patients will soon be able to buy and medicate…
Read More →

Arfinn Med Patient Site

We get a lot of interest from patients asking about efficacy data for medical marijuana on a number of conditions. Though we are primarily an electronic medical record (EMR) company focussing on the cannabis industry and other complimentary or alternative therapies, our primary focus is better quality care for patients. So with that being said,…
Read More →

States with medical marijuana laws saw 20 percent drop in some opioid prescriptions

States with active medical marijuana laws saw certain opioid prescription rates drop nearly 20 percent compared to states without medical marijuana programs, according to a first-of-its-kind study out of Columbia University’s Irving Medical Center. Authors said the findings underscore the importance of providing patients with pain management alternatives, such as cannabis, in efforts to reduce…
Read More →

Systematic review: Efficacy and safety of medical marijuana in selected neurologic disorders

Report of the Guideline Development Subcommittee of the American Academy of Neurology:   We performed a systematic review of medical marijuana (1948–November 2013) to address treatment of symptoms of multiple sclerosis (MS), epilepsy, and movement disorders. We graded the studies according to the American Academy of Neurology classification scheme for therapeutic articles. Read the full…
Read More →

PTSD and Cannabis

Post-Traumatic Stress Disorder (PTSD) is a psychiatric disorder that occurs in people who witnessed or have gone through a traumatic event.  That can include events such as  natural disasters, war/combat, a serious accident, or personal assault, among others.  People suffering from PTSD have disturbing thoughts and feelings related to the traumatic event that can last…
Read More →

LEGALIZING CANNABIS LINKED TO LESS OPIOID PRESCRIPTIONS, COULD HELP COMBAT EPIDEMIC, SCIENTISTS SAY

There are less opioid prescriptions on average in U.S. states where medical and recreational marijuana are legal, research has revealed. Access to recreational cannabis in the U.S. was tied with a 11.8 percent lower rate of opioids prescriptions each day, and 4.2 percent for medical marijuana. The authors of the paper published in the Journal of Health Economics said recreational weed…
Read More →

Leave a Comment

You must be logged in to post a comment.